ZA959469B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA959469B
ZA959469B ZA959469A ZA959469A ZA959469B ZA 959469 B ZA959469 B ZA 959469B ZA 959469 A ZA959469 A ZA 959469A ZA 959469 A ZA959469 A ZA 959469A ZA 959469 B ZA959469 B ZA 959469B
Authority
ZA
South Africa
Prior art keywords
pct
date
sec
steroidal anti
inflammatory drug
Prior art date
Application number
ZA959469A
Other languages
English (en)
Inventor
Lawrence John Penkler
Lueta Ann Glintenkamp
Douglas George Murra Nicholson
Michiel Coenraad Bo Oudtshoorn
Original Assignee
South African Druggists Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South African Druggists Ltd filed Critical South African Druggists Ltd
Publication of ZA959469B publication Critical patent/ZA959469B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA959469A 1994-11-15 1995-11-08 Pharmaceutical composition ZA959469B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA949055 1994-11-15

Publications (1)

Publication Number Publication Date
ZA959469B true ZA959469B (en) 1996-05-15

Family

ID=25584578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959469A ZA959469B (en) 1994-11-15 1995-11-08 Pharmaceutical composition

Country Status (9)

Country Link
US (1) US5854226A (de)
EP (1) EP0792147B1 (de)
JP (1) JPH10508835A (de)
CN (1) CN1171738A (de)
AT (1) ATE261301T1 (de)
AU (1) AU694577B2 (de)
DE (1) DE69532678D1 (de)
WO (1) WO1996014839A1 (de)
ZA (1) ZA959469B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482377B2 (en) * 1996-05-17 2009-01-27 Kowa Pharmaceuticals America, Inc. Pharmaceutical compositions and methods of treatment based on diclofenac

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
US7687542B2 (en) 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
FR2768339A1 (fr) * 1997-09-18 1999-03-19 Neufville Axel De Utilisation d'un oxicam en tant qu'anti-migraineux
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
JP5026635B2 (ja) 1998-09-10 2012-09-12 ニュコメデ ダンマルク アンパーツセルスカブ 医薬物質の迅速放出医薬組成物
DE19912436A1 (de) * 1999-03-19 2000-09-21 Merckle Gmbh Ibuprofen-Lösung
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
ES2450648T3 (es) * 2004-06-29 2014-03-25 Takeda Pharma A/S Fabricación de composiciones farmacéuticas con liberación rápida de fármacos insolubles en agua y composiciones farmacéuticas obtenidas mediante el procedimiento de la invención
AU2005260243B2 (en) 2004-07-07 2009-10-29 Aft Pharmaceuticals Limited A combination composition
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
EP1814575A4 (de) * 2004-11-24 2010-07-07 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von leiden
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
AU2006317530B2 (en) 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US7939561B2 (en) 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens
US7700125B2 (en) 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
JP5823093B2 (ja) * 2006-03-28 2015-11-25 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
US7985542B2 (en) 2006-09-07 2011-07-26 Institut Pasteur Genomic morse code
EP1974751A1 (de) * 2007-03-26 2008-10-01 The Jordanian Pharmaceutical Manufacturing Co. Formulierungen für nichtsteroidale entzündungshemmende Arzneimittel
JP2010527377A (ja) 2007-05-17 2010-08-12 ネオプロ ラブス，エルエルシー ペプチドの結晶形および非結晶形
CA2692844C (en) 2007-06-07 2019-02-12 Simons Haplomics Limited In situ methods for gene mapping and haplotyping
US20090069237A1 (en) * 2007-07-18 2009-03-12 Hanna Skubatch Methods and compositions for treating conditions
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011013019A1 (en) 2009-07-31 2011-02-03 Centre Hospitalier Universitaire Vaudois Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
US20110052679A1 (en) 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms
GB0922377D0 (en) 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
EP2394641A1 (de) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmazeutische Formulationen von Lornoxicam
EP2726632A1 (de) 2011-06-30 2014-05-07 Centre Hospitaller Universitaire Vaudois (CHUV) Polymorphismen in zusammenhang mit fehlendem ansprechen auf eine hepatitis-c-behandlung oder der anfälligkeit für nicht-spontane hepatitis-c-heilung
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
EP3415153A1 (de) * 2012-01-30 2018-12-19 Baxalta GmbH Nicht-antikoagulierende sulfatierte oder sulfonierte polysaccharide
SI3256138T1 (sl) * 2015-11-25 2022-07-29 Axsome Therapeutics, Inc. Farmacevtski sestavki, ki obsegajo meloksikam
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
WO2018100431A1 (en) 2016-11-29 2018-06-07 Genomic Vision Method for designing a set of polynucleotide sequences for analysis of specific events in a genetic region of interest
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
EP0519428B1 (de) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
GB9316580D0 (en) * 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AU2531295A (en) * 1994-05-27 1995-12-21 Farmarc Nederland Bv Pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482377B2 (en) * 1996-05-17 2009-01-27 Kowa Pharmaceuticals America, Inc. Pharmaceutical compositions and methods of treatment based on diclofenac

Also Published As

Publication number Publication date
WO1996014839A1 (en) 1996-05-23
CN1171738A (zh) 1998-01-28
US5854226A (en) 1998-12-29
EP0792147B1 (de) 2004-03-10
DE69532678D1 (de) 2004-04-15
JPH10508835A (ja) 1998-09-02
ATE261301T1 (de) 2004-03-15
EP0792147A1 (de) 1997-09-03
AU694577B2 (en) 1998-07-23
AU3853895A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
ZA959469B (en) Pharmaceutical composition
DZ1884A1 (fr) Formulations orales liquides d'alendronate.
AU1079701A (en) Oral transmucosal drug dosage using solid solution
EP1243269A3 (de) Opioidformulierungen mit verlängerter gesteuerter Wirkstoffabgabe
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
HUP0204159A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
IE60241B1 (en) Antitussive liquid compositions containing phenol
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
CA2350396A1 (en) A composition useful to treat periodontal disease
JP2000063268A (ja) 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
KR950031049A (ko) 풍미된 필름 제피를 함유하는 고형의 약제학적 용량형
WO2001039760A3 (en) Method of treating batten disease
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
Turner Maalox. Antacid: see ALUMINIUM
BENSERAZIDE et al. conditions: see DEXAMETHASONE
WO2001028566B1 (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
Turner Marcain. Local anaesthetic injection
MD1469G2 (ro) Metodă de tratament al şocului combustional
Turner Marplan. Antidepressant (monoamine oxidase inhibitor): see ISOCARBOXAZID. Marvelon. Oral contraceptive: see